<button id="eiezk"><video id="eiezk"></video></button>

產(chǎn)品名稱

Golvatinib - E 7050

產(chǎn)品貨號

Axon 1959 CAS [928037-13-2] MF C33H37F2N7O4MW 633.69 Purity: 99% Soluble in 0.1N HCl(aq) and DMSO Description Potent and orally available inhibitor of c-MET (HGFR) (IC50: 14 nM) and VEGFR2 (IC50: 16 nM); Golvatinib inhibits the activities of both c-Met and VEGFR2, which may inhibit tumor cell growth and survival of tumor cells that overexpress these receptor tyrosine kinases References Certificates Categories Extra info T Nakagawa et al. E7050: A dual c-Met and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models. Cancer Science 2010, 101(1), 210-215.? ? W Wang et al. Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer. Clin Cancer Res. 2012, 18(6):1663-1671.? Certificate of Analysis Material Safety Data Sheet Angiogenesis Cell Signaling & Oncology c-MET VEGFR RTK class IV and X; EC 2.7.10.1 Potent and orally available inhibitor of c-MET (HGFR) and VEGFR2 Chemical name N-(2-fluoro-4-(2-(4-(4-methylpiperazin-1-yl)piperidine-1-carboxamido)pyridin-4-yloxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide Parent CAS No. [928037-13-2] Order Size Unit Price Stock 10 mg €95.00 In Stock

產(chǎn)品價格

現(xiàn)貨詢價，電話：010-67529703

產(chǎn)品規(guī)格

產(chǎn)品品牌

axonmedchem

產(chǎn)品概述

產(chǎn)品詳情

Golvatinib - E 7050

Based on 15 reference(s) in Google Scholar 8 10 15

Axon 1959

CAS [928037-13-2]

MF C33H37F2N7O4
MW 633.69

Purity: 99%
Soluble in 0.1N HCl(aq) and DMSO

Golvatinib

Description

Potent and orally available inhibitor of c-MET (HGFR) (IC50: 14 nM) and VEGFR2 (IC50: 16 nM); Golvatinib inhibits the activities of both c-Met and VEGFR2, which may inhibit tumor cell growth and survival of tumor cells that overexpress these receptor tyrosine kinases

T Nakagawa et al. E7050: A dual c-Met and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models. Cancer Science 2010, 101(1), 210-215.?

W Wang et al. Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer. Clin Cancer Res. 2012, 18(6):1663-1671.?

Certificate of Analysis
Material Safety Data Sheet

Angiogenesis Cell Signaling & Oncology c-MET VEGFR RTK class IV and X; EC 2.7.10.1

Potent and orally available inhibitor of c-MET (HGFR) and VEGFR2

Chemical name

N-(2-fluoro-4-(2-(4-(4-methylpiperazin-1-yl)piperidine-1-carboxamido)pyridin-4-yloxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide

Parent CAS No.

[928037-13-2]

產(chǎn)品資料

<button id="eiezk"><video id="eiezk"></video></button>